Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 3
2005 2
2006 4
2007 1
2008 2
2009 1
2010 4
2011 5
2012 4
2013 6
2014 4
2015 6
2016 5
2017 6
2018 7
2019 6
2020 21
2021 27
2022 31
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Results by year
Filters applied: . Clear all
Page 1
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F. Carreño JM, et al. Among authors: simon v. Vaccine. 2022 Sep 14:S0264-410X(22)01003-9. doi: 10.1016/j.vaccine.2022.08.024. Online ahead of print. Vaccine. 2022. PMID: 36115801 Free PMC article.
Furthermore, we observed the same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA formulation and found that the reactivity of such antibodies correlated well with antibody levels against high and low molecular weight PEG. ...
Furthermore, we observed the same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA formulati …
A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants.
Hernandez MM, Banu R, Shrestha P, Gonzalez-Reiche AS, van de Guchte A, Farrugia K, Sebra R; Mount Sinai PSP Study Group, Gitman MR, Nowak MD, Cordon-Cardo C, Simon V, van Bakel H, Sordillo EM, Luna N, Ramirez A, Castañeda SA, Patiño LH, Ballesteros N, Muñoz M, Ramírez JD, Paniz-Mondolfi AE. Hernandez MM, et al. Among authors: simon v. Microbiol Spectr. 2022 Sep 7:e0173622. doi: 10.1128/spectrum.01736-22. Online ahead of print. Microbiol Spectr. 2022. PMID: 36069609 Free article.
Furthermore, until WGS becomes more accessible in the clinical microbiology laboratory, the ideal assay for identifying variants must be robust, provide high resolution, and be adaptable to the evolving nature of viruses like SARS-CoV-2. Here, we highlighted the diagnostic …
Furthermore, until WGS becomes more accessible in the clinical microbiology laboratory, the ideal assay for identifying variants must be rob …
Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model.
Tan J, Chromikova V, O'Dell G, Sordillo EM, Simon V, van Bakel H, Krammer F, McMahon M. Tan J, et al. Among authors: simon v. mSphere. 2022 Sep 7:e0092721. doi: 10.1128/msphere.00927-21. Online ahead of print. mSphere. 2022. PMID: 36069438 Free article.
Current influenza virus vaccines and antivirals have limitations, some of which disproportionately affect their utilization against influenza B viruses. ...Although two antigenically distinct influenza B virus lineages cocirculated before the coronavirus dise …
Current influenza virus vaccines and antivirals have limitations, some of which disproportionately affect their utilization against i …
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Duty JA, et al. Among authors: simon v. Med (N Y). 2022 Aug 8:S2666-6340(22)00321-X. doi: 10.1016/j.medj.2022.08.002. Online ahead of print. Med (N Y). 2022. PMID: 36044897 Free PMC article.
FINDINGS: STI-9167 has potent, broad-spectrum neutralizing activity against the current SARS-COV-2 variants of concern and retained activity against each of the tested Omicron subvariants in both pseudotype and live virus neutralization assays. Furthermore, STI-9167 nAb ad …
FINDINGS: STI-9167 has potent, broad-spectrum neutralizing activity against the current SARS-COV-2 variants of concern and retained activity …
SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants.
Kubale J, Gleason C, Carreño JM, Srivastava K, Singh G; PARIS Study Team, Gordon A, Krammer F, Simon V. Kubale J, et al. Among authors: simon v. mBio. 2022 Aug 23:e0178422. doi: 10.1128/mbio.01784-22. Online ahead of print. mBio. 2022. PMID: 35997286 Free article.
In conclusion, SARS-CoV-2 antibody titers mounted upon infection are stable over several months and provide protection from infection with antigenically similar viruses. IMPORTANCE SARS-CoV-2 is the cause of one of the largest noninfluenza pandemics of this century. ...SAR …
In conclusion, SARS-CoV-2 antibody titers mounted upon infection are stable over several months and provide protection from infection with a …
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.
Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuita NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N; IMPACC study group members. Ozonoff A, et al. Among authors: simon v. EBioMedicine. 2022 Sep;83:104208. doi: 10.1016/j.ebiom.2022.104208. Epub 2022 Aug 8. EBioMedicine. 2022. PMID: 35952496 Free PMC article.
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: simon v. N Engl J Med. 2022 Aug 4;387(5):468-470. doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857646 Free PMC article. No abstract available.
Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera.
Rathnasinghe R, Jangra S, Ye C, Cupic A, Singh G, Martínez-Romero C, Mulder LCF, Kehrer T, Yildiz S, Choi A, Yeung ST, Mena I, Gillespie V, De Vrieze J, Aslam S, Stadlbauer D, Meekins DA, McDowell CD, Balaraman V, Corley MJ, Richt JA, De Geest BG, Miorin L; PVI study group, Krammer F, Martinez-Sobrido L, Simon V, García-Sastre A, Schotsaert M. Rathnasinghe R, et al. Among authors: simon v. Nat Commun. 2022 Jul 7;13(1):3921. doi: 10.1038/s41467-022-30763-0. Nat Commun. 2022. PMID: 35798721 Free PMC article.
Here we show that serial passaging of USA-WA1/2020 strain in mouse lungs results in "mouse-adapted" SARS-CoV-2 (MA-SARS-CoV-2) with mutations in S, M, and N genes, and a twelve-nucleotide insertion in the S gene. ...We further show that S protein mutations of …
Here we show that serial passaging of USA-WA1/2020 strain in mouse lungs results in "mouse-adapted" SARS-CoV-2 (MA-SARS-CoV-2) with mutation …
Development of an HIV reporter virus that identifies latently infected CD4+ T cells.
Kim EH, Manganaro L, Schotsaert M, Brown BD, Mulder LCF, Simon V. Kim EH, et al. Among authors: simon v. Cell Rep Methods. 2022 Jun 13;2(6):100238. doi: 10.1016/j.crmeth.2022.100238. eCollection 2022 Jun 20. Cell Rep Methods. 2022. PMID: 35784650 Free PMC article.
There is no cure for HIV infection, as the virus establishes a latent reservoir, which escapes highly active antiretroviral treatments. ...LTR-silent integrations occurred to variable degrees in all CD4(+) T subsets examined, with CD4(+) T(EM) and CD4(+) T(REG) disp …
There is no cure for HIV infection, as the virus establishes a latent reservoir, which escapes highly active antiretroviral tr …
141 results